New England Journal of Medicine· 2021Q1

Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma

Paul Nathan, Jessica C. Hassel, Piotr Rutkowski, Jean‐François Baurain et al.

888citations
Q1SCImago
2021year

Short summary

Tebentafusp significantly improved 1-year overall survival by 14% (73% vs. 59%) in previously untreated metastatic uveal melanoma patients compared to investigator's choice of therapy (pembrolizumab, ipilimumab, or dacarbazine) in a Phase 3 trial (n=378).

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Ophthalmology

OphthalmologyMedicine